Leerink Partnrs Issues Optimistic Estimate for BCYC Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Investment analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for Bicycle Therapeutics in a research note issued on Monday, January 13th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($3.01) for the year, up from their previous estimate of ($3.03). The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Bicycle Therapeutics’ Q4 2024 earnings at ($0.83) EPS, Q1 2025 earnings at ($0.84) EPS, Q2 2025 earnings at ($0.86) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.87) EPS and FY2025 earnings at ($3.43) EPS.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities lowered their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday. B. Riley lowered their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Finally, Stephens initiated coverage on Bicycle Therapeutics in a report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Bicycle Therapeutics Stock Down 1.8 %

Shares of Bicycle Therapeutics stock opened at $14.55 on Thursday. The firm has a market cap of $1.00 billion, a PE ratio of -4.42 and a beta of 0.92. The business has a 50-day moving average price of $17.99 and a 200 day moving average price of $21.56. Bicycle Therapeutics has a twelve month low of $12.17 and a twelve month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04. The firm had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business’s quarterly revenue was down 50.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.26) EPS.

Insiders Place Their Bets

In other Bicycle Therapeutics news, insider Santiago Arroyo sold 4,943 shares of Bicycle Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $69,646.87. Following the transaction, the insider now directly owns 69,057 shares of the company’s stock, valued at $973,013.13. The trade was a 6.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 985,397 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was purchased at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now owns 9,537,643 shares in the company, valued at approximately $131,237,967.68. This trade represents a 11.52 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 33,933 shares of company stock valued at $549,501. Insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Several large investors have recently modified their holdings of the business. FMR LLC purchased a new stake in Bicycle Therapeutics in the 3rd quarter valued at about $3,406,000. The Manufacturers Life Insurance Company raised its stake in shares of Bicycle Therapeutics by 33.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after acquiring an additional 32,313 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter worth approximately $10,028,000. State Street Corp lifted its holdings in shares of Bicycle Therapeutics by 233.5% in the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock worth $1,952,000 after acquiring an additional 60,399 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new position in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $11,577,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.